CN101428044A - Novel broad spectrum antiphlogistic pain-easing medicament for treating multiple oral diseases - Google Patents
Novel broad spectrum antiphlogistic pain-easing medicament for treating multiple oral diseases Download PDFInfo
- Publication number
- CN101428044A CN101428044A CNA2007101663083A CN200710166308A CN101428044A CN 101428044 A CN101428044 A CN 101428044A CN A2007101663083 A CNA2007101663083 A CN A2007101663083A CN 200710166308 A CN200710166308 A CN 200710166308A CN 101428044 A CN101428044 A CN 101428044A
- Authority
- CN
- China
- Prior art keywords
- oral
- mansostin
- mangostin
- oral diseases
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a novel broad-spectrum anti-inflammation analgesic drug for curing various oral diseases. The invention discloses a main compound extracted from mangosteen:Garcinia mangostana, i.e. mangostin, the mangostin is taken as the maim active component and combined with the commonly-used filling agents in various pharmaceutical industries to be prepared into various dosage forms or as drugs, health care products, food additives and the like, and the mangostin can be internally and externally used for ulcerative stomatitis, pharyngitis and the like, and also can be used for preening and curing the oral diseases, for example, the benign and malignant tumors of oral cavity. The content of the mangostin is between 1.2 and 99.8 percent, can be separately used or used by matching other substances, and also can be used for preventing and curing the oral diseases of animals. The product overcomes the defects in the prior drug for curing the oral diseases, such as poor effect, irritability, high recurrence rate, side-effect and the like, and is the efficient and broad-spectrum new drug with anti-inflammation, rapid abirritation, non-toxicity, no side-effect and enhanced immunity.
Description
Technical field:
It is the multiple disease of commonly encountered diseases that oral diseases such as the optimum and malignant tumor of oral inflammation in the oral disease and oromaxillo-facial region belong to, and comprising: oral diseases such as oral ulcer, chronic pharyngitis, tonsillitis (comprising upper respiratory tract infection), mixed tumor of salivary gland, epulis, hemangioma, lymphangioma, neurofibroma, fibroma, giant cell tumor, osteoma, odontoma, ameloblastoma, squamous cell carcinoma etc.The pathogeny more complicated of oral disease, usually with wound, heredity, excessive work, Nervous and Mental Factors, some vitamin and trace element lacks, immunological diseases and other disease have close getting in touch, be usually expressed as hyperemia, edema, itch or pain, fester, symptoms such as hemorrhage, lymphadenectasis, herpes, sialorrhea, dysmasesis, halitosis, canceration.At present medical needles adopts antibiotic, hormone medicine, chemoradiotherapy, operation or the like traditional therapy to oral inflammation, tumor more, and relapse rate height, side effect are big, cause a lot of miseries and psychological pressure to the patient.
Product of the present invention has overcome painful big, the weak effect of at present existing treatment oral disease, zest has been arranged, relapse rate is high and defective such as side effect is arranged.Can take, be used to treat the optimum and malignant tumor of oral inflammation and oromaxillo-facial region outward, have significant antiinflammatory, analgesic activity reach rapidly nontoxic, have no side effect and improve the immunity effect.
Background of invention:
The present invention is for containing Cortex Garciniae (mangosteen:Garcinia Mangostana) extract, it mainly contains effective constituent is alpha mansostin (alpha-mangostin), its content range is that 1.2%～99.8% conduct of taking dose mainly contains effective constituent, cooperate suitable filler, make new product with anti-inflammatory analgesic.
Mansostin can be to extract from natural Cortex Garciniae shell or sarcocarp, can also be to produce by the method for chemosynthesis.
Compare with NSAID (non-steroidal anti-inflammatory drug) with existing steroid hormone class, the side effect of α-mansostin little (or avirulence), also non-stimulated to the intestines and stomach.α-mansostin is to extract from plant, has effects such as antiinflammatory, convulsion, inhibition monoamine oxidase, MAO.The range of application that α-mansostin and γ-mansostin have comprises and can be used as oral and the externally applied anti-inflammation medicine, and is effectual to oral disease.Toxicological study experimental results show that in acute toxicity testing, and we are increased to the denseest level (people's dose 400 times) with dosage and do not measure fatal dose (LD50) yet, prove very safe; In addition, do not see the relevant report of α-mansostin and other medicines restriction or checking relation in five elements in the document so far yet in research.
Because Cortex Garciniae contains more α-mansostin, secondly is γ-mansostin, β-mansostin then has only on a small quantity.The research that we did just concentrates on α-mansostin and γ-mansostin.α-mansostin and γ-mansostin have good anti-inflammatory analgesic effect, and cell permeability is strong, and porous is eliminated inflammation to the health different tissues, and effective, required dosage is quite low, does not also find obvious toxic and side effects rapidly for effect.
Experimental results show that α-mansostin and γ-mansostin unite to use has good synergism.So present invention includes the prescription that independent use α-mansostin and associating γ-mansostin use together.
Summary of the invention:
The prescription of multiple different proportion is contained in the present invention, be used for the treatment of the acinus atrophy of oral ulcer, pharyngitis, tonsillitis, periodontitis, gingivitis, herpes, parotitis, pharyngolaryngitis, minor salivary glands and the optimum and malignant tumor that mostly occurs at the oromaxillo-facial region of tongue, cheek, lip, gingiva, palate, maxillary sinus, comprise: mixed tumor of salivary gland, epulis, hemangioma, lymphangioma, neurofibroma, fibroma, giant cell tumor, osteoma, odontoma, ameloblastoma, squamous cell carcinoma etc., and reduce inflammation to a certain extent and the misery at neoplastic lesion position.
Raw material that product of the present invention makes can be from whole Cortex Garciniae shell and sarcocarp, by water or ethanol method of purification, obtains the purification thing that contains (5-95%) xanthone (xanthones); These purification things include 2-75% α-mansostin [alpha (α)-mangostin] and can directly be used as and mainly contain effective constituent, cooperate other filler, make suitable dosage form, be used for the treatment of the multiple indication that the present invention declares: it is the multiple disease of commonly encountered diseases that oral diseases such as the optimum and malignant tumor of oral inflammation and oromaxillo-facial region belong to, comprise: oral ulcer, chronic pharyngitis, oral diseases such as tonsillitis (comprising upper respiratory tract infection), mixed tumor of salivary gland, epulis, hemangioma, lymphangioma, neurofibroma, fibroma, giant cell tumor, osteoma, odontoma, ameloblastoma, diseases such as squamous cell carcinoma are removed the affected part hyperemia that causes because of above-mentioned disease, edema, itch or pain, fester, hemorrhage, lymphadenectasis, herpes, sialorrhea, dysmasesis, halitosis, symptoms such as canceration.Utilize the Cortex Garciniae extract further α-mansostin to be purified to more than 98%, as the concentrated dosage form of the above-mentioned sufferer of treatment.
Cortex Garciniae (mangosteen:Garcinia Mangostana) is a kind of common fruit plant, and its shell and sarcocarp have some drug effects, is widely used in antiulcer in south east asia, controls diarrhoea and germ-resistant conventional medicament.Wherein isolated α-, β-and γ-mansostin, and multiple different xanthone material (xanthones), be the chemical compound of its main biologically active, have in various degree antiinflammatory, sterilization, anti-amebic dysentery and antiulcer activity.We discover α-, β-and γ-mansostin can suppress Cycloxygenase and sphingomyelinase, antagonism histamine receptor and 5-hydroxytryptamine receptor effectively and have antioxidation, pharmacological action such as antibiotic.We invent multiple different formulations, by zoopery and crowd's test, the proof α-, β-and γ-mansostin the good cell permeability is arranged, this great discovery make α-, β-and γ-mansostin can become the various inflammation of treatment some existing antibiotic medicine (alclometasone diproionate and non-steroidal medicine) poor effect: oral diseases such as the acinus atrophy of oral ulcer, pharyngitis, tonsillitis, periodontitis, gingivitis, herpes, parotitis, pharyngolaryngitis, minor salivary glands and oral cavity and throat tumor have significant anti-inflammatory and antalgic effect.
The specific embodiment:
Multiple prescription is in proportion contained in the present invention, and effect is a treatment oral system disease.The employed effective constituent that mainly contains is alpha mansostin (alpha-mangostin), its content range is 1.2%～99.8% of a taking dose, cooperate suitable filler, making Shen cellulose content is 2mg～10g, product can be made into tablet, capsule, pill, powder, spray, the injection of 2mg～10g or other dosage form is taken, injection or external, and the every day of manufactured goods is oral or other using dosage should be no less than 1.2mg.Product of the present invention have antiinflammatory, analgesic activity reach rapidly nontoxic, have no side effect and improve the new product of effect of immunity.The disease of main treatment comprises: oral diseases such as the acinus atrophy of oral ulcer, pharyngitis, tonsillitis, periodontitis, gingivitis, herpes, parotitis, pharyngolaryngitis, minor salivary glands and mixed tumor of salivary gland, epulis, hemangioma, lymphangioma, neurofibroma, fibroma, giant cell tumor, osteoma, odontoma, ameloblastoma, squamous cell carcinoma.
Claims (9)
1. the present invention is a kind of novel broad spectrum antiphlogistic analgesic for the treatment of multiple oral disease, the present invention contains Cortex Garciniae (mangosteen:GarciniaMangostana) extract, it mainly contains effective constituent is alpha mansostin (alpha-mangostin), its content range is 1.2%～99.8% of a taking dose, and as mainly containing effective constituent, cooperate suitable filler, make antiinflammatory, analgesia, raising immunologic function, have no side effect at oral disease, non-stimulated, act on new product rapidly.
2. mansostin according to claim 1 can be to extract from natural Cortex Garciniae shell or sarcocarp, also can be to produce by the method for chemosynthesis.
3. the each use amount of mansostin according to claim 1 is 1.2mg～500mg, a kind of novel drugs that is used for the treatment of the oral diseases such as acinus atrophy of oral ulcer, pharyngitis, tonsillitis, periodontitis, gingivitis, herpes, parotitis, pharyngolaryngitis, minor salivary glands, and tangible analgesic effect arranged, and remove because of affected part hyperemia, edema that above-mentioned disease causes, itch or pain, fester, symptoms such as hemorrhage, lymphadenectasis, herpes, sialorrhea, dysmasesis, halitosis.
4. the each use amount of mansostin according to claim 1 is 1.2mg～10g, be used for the optimum and malignant tumor of prevention and treatment oral cavity, comprise: a kind of novel drugs of mixed tumor of salivary gland, epulis, hemangioma, lymphangioma, neurofibroma, fibroma, giant cell tumor, osteoma, odontoma, ameloblastoma, squamous cell carcinoma etc., and tangible analgesic effect arranged, and remove because of affected part hyperemia, edema that above-mentioned disease causes, itch or pain, fester, symptoms such as hemorrhage, lymphadenectasis, herpes, sialorrhea, dysmasesis, halitosis.
According to claim 1 described in employed Cortex Garciniae extract, be equipped with suitable filler, make tablet, capsule, pill, powder, spray, injection or other dosage form is taken, injection or external, and the every day of manufactured goods is oral or other using dosage should be no less than 1.2mg.
6. spill cellulose content according to claim 1 is 1.2mg～10g, and all the other are suitable filler, can be made into tablet, capsule, injection, powder, spray or other dosage forms of 5mg～10g, the convenient use.
7. suitable filler be can add according to the prescription in the claim 1 and edible solvent, stabilizing agent, lubricant, coating agent, antiseptic and emulsifying agent etc. comprised.
8. be no less than under the prerequisite of each use amount 1.2mg according to the contained mangostin of the prescription in the claim 1, can be used as and be used for material additive, add in the products such as medicine, health product, health food, food such as throat lozenge, toothpaste, collutory, chewing gum, can play the effect of treatment and health care.
9. Shen cellulose content according to claim 1 is the 0.3mg-500mg/Kg weight ratio, also can be used for other vertebrates and takes, and the animal pharmaceuticals that is used for the treatment of the various oral inflammations of animal and mouth neoplasm etc. is used.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101663083A CN101428044A (en) | 2007-11-06 | 2007-11-06 | Novel broad spectrum antiphlogistic pain-easing medicament for treating multiple oral diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101663083A CN101428044A (en) | 2007-11-06 | 2007-11-06 | Novel broad spectrum antiphlogistic pain-easing medicament for treating multiple oral diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101428044A true CN101428044A (en) | 2009-05-13 |
Family
ID=40643812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007101663083A Pending CN101428044A (en) | 2007-11-06 | 2007-11-06 | Novel broad spectrum antiphlogistic pain-easing medicament for treating multiple oral diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101428044A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011068814A1 (en) * | 2009-12-04 | 2011-06-09 | Colgate-Palmolive Company | Oral compositions containing extracts of garcinia mangostana l. and related methods |
| CN101612147B (en) * | 2009-07-24 | 2012-08-22 | 中山大学 | Application of alpha-mangostin in preparing inflammation-resisting pain-relieving medicine |
| WO2014013727A1 (en) * | 2012-07-19 | 2014-01-23 | 株式会社ロッテ | Immunemodulating agent |
| CN103976127A (en) * | 2014-05-29 | 2014-08-13 | 叶新 | Mangosteen-flavored chewing gum and preparation method thereof |
| CN105218507A (en) * | 2015-09-30 | 2016-01-06 | 中国药科大学 | A kind of Norathyriol derivative and its production and use |
| WO2017018906A1 (en) * | 2015-07-30 | 2017-02-02 | Общество С Ограниченной Ответственностью "Джи-Дерм Стома" | Medicinal mouthwash for the gums |
| CN106794210A (en) * | 2014-09-16 | 2017-05-31 | 株式会社梅迪生物实验室 | Comprising mangosteen extract or α, γ mangostin as the periodontosis prevention of active ingredient or improvement composition |
-
2007
- 2007-11-06 CN CNA2007101663083A patent/CN101428044A/en active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101612147B (en) * | 2009-07-24 | 2012-08-22 | 中山大学 | Application of alpha-mangostin in preparing inflammation-resisting pain-relieving medicine |
| WO2011068814A1 (en) * | 2009-12-04 | 2011-06-09 | Colgate-Palmolive Company | Oral compositions containing extracts of garcinia mangostana l. and related methods |
| CN102762259A (en) * | 2009-12-04 | 2012-10-31 | 高露洁-棕榄公司 | Oral compositions containing extracts of garcinia mangostana and related methods |
| EP2689805A1 (en) * | 2009-12-04 | 2014-01-29 | Colgate-Palmolive Company | Oral compositions containing extracts of garcinia mangostana l. and related methods |
| WO2014013727A1 (en) * | 2012-07-19 | 2014-01-23 | 株式会社ロッテ | Immunemodulating agent |
| CN103976127A (en) * | 2014-05-29 | 2014-08-13 | 叶新 | Mangosteen-flavored chewing gum and preparation method thereof |
| CN106794210A (en) * | 2014-09-16 | 2017-05-31 | 株式会社梅迪生物实验室 | Comprising mangosteen extract or α, γ mangostin as the periodontosis prevention of active ingredient or improvement composition |
| WO2017018906A1 (en) * | 2015-07-30 | 2017-02-02 | Общество С Ограниченной Ответственностью "Джи-Дерм Стома" | Medicinal mouthwash for the gums |
| CN105218507A (en) * | 2015-09-30 | 2016-01-06 | 中国药科大学 | A kind of Norathyriol derivative and its production and use |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101428044A (en) | Novel broad spectrum antiphlogistic pain-easing medicament for treating multiple oral diseases | |
| JP2020073582A (en) | Crude-drug-containing pharmaceutical composition | |
| RU2450819C2 (en) | Herbal compositions for treating oral diseases | |
| CN106794210A (en) | Comprising mangosteen extract or α, γ mangostin as the periodontosis prevention of active ingredient or improvement composition | |
| EP1444984B1 (en) | Topical pharmaceutical compositions containing natural active constituents suitable for the prevention and treatment of mucosal inflammation processes | |
| CN104706616A (en) | Effervescent compositions | |
| CN101428046A (en) | Novel broad spectrum antiphlogistic pain-easing externally used medicament | |
| WO2020072850A1 (en) | Compositions and methods for promoting and maintaining oral health | |
| US10675269B2 (en) | Compositions comprising melatonin | |
| CN106692755B (en) | Traditional Chinese medicine composition with hemostatic, anti-inflammatory and antibacterial functions and preparation method and application thereof | |
| CN109431976A (en) | A kind of drug of anti-oral ulcer and application thereof | |
| RU2240131C1 (en) | Agent "artrovit" for prophylaxis and treatment of arthritis and arthrosis | |
| WO2012131643A1 (en) | Herbal compositions comprising pedilanthus tithymaloides for treatment prevention of gastrointestinal disorder | |
| CN104906132B (en) | A kind of plaster for preventing and treating lamb stomatitis | |
| KR102141623B1 (en) | Composition for prevention or treatment of dental disease comprising an extract of cinnamon | |
| CN107343926B (en) | Traditional Chinese medicine composition for treating recurrent oral ulcer | |
| RU2481111C1 (en) | Method for prevention of gastric mucosa ulceration | |
| CN101428045A (en) | Novel medicament of plants for treating multiple diseases of female reproductive system | |
| KR101078765B1 (en) | Edible composition for prevention of periodontal disease by growth of bacteria in the mouth | |
| CN105997949B (en) | A kind of bulleyaconitine A orodispersible film preparation and its preparation process | |
| KR102439853B1 (en) | Compositions for preventing or treating periodontal disease comprising extract of maple | |
| CN104644659B (en) | 20 (R) ginseng sapoglycoside Rg 3s are preparing the application in alleviating and/or treating pharyngitis medicine | |
| CN104906131B (en) | A kind of preparation method preventing and treating lamb stomatitis plaster | |
| JPH02193926A (en) | Gastrointestinal drug | |
| CN101322741A (en) | Chinese medicinal composition for treating periodontitis and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090513 |